Xenetic expands collaboration with The Scripps Research Institute

Xenetic (XBIO) Biosciences has continued its collaboration with The Scripps Research Institute to advance the development of the Company’s development program evaluating the combination of systemic DNase I and CAR T-cell therapies. Xenetic’s systemic DNase I candidate, XBIO-015, is currently in preclinical development in combination with CAR-T cell therapy for both hematologic and solid tumors. Studies conducted at TSRI using lymphoma and metastatic melanoma models have shown that co-administration of DNase I with CAR-T cells significantly reduces tumor burden, decreases metastatic lesions, and markedly extends survival compared to CAR-T cell monotherapy. Importantly, systemic DNase I-mediated degrading of neutrophil extracellular trapsenhances CAR-T cell efficacy increasing the infiltration of both CAR-T cells and endogenous T cells into tumors and by mitigating the immunosuppressive tumor microenvironment. Based on these results, the research program has been expanded to include additional models of lymphoma and leukemia to further validate these findings.